Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization.

Blood - 18 Dec 2014

Avbelj Monika, Wolz Olaf-Oliver, Fekonja Ota, Benčina Mojca, Repič Matej, Mavri Janez, Krüger Jens, Schärfe Charlotta, Delmiro Garcia Magno, Panter Gabriela, Kohlbacher Oliver, Weber Alexander N R, Jerala Roman

Abstract excerpt

Myeloid differentiation 88 (MyD88) is the key signaling adapter of Toll-like and interleukin-1 receptors. Recurrent lymphoma-associated mutations, particularly Leu265Pro (L265P), within the MyD88 Toll/interleukin-1 receptor (TIR) domain sustain lymphoma cell survival due to constitutive nuclear factor κB signaling. We found that mutated TIR domains displayed an intrinsic propensity for augmented oligomerization...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allosteric Site
Share to Luminescence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma

Share to Microscopy, Confocal

Share to Molecular Dynamics Simulation

Share to Myeloid Differentiation Factor 88

Share to Receptors, Interleukin-1

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 25359991
DOI: 10.1182/blood-2014-05-573188
PMCID: PMC4282153

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization.PMID 25359991Read ↗

Oncogenically active MYD88 mutations in human lymphoma.Semantic proximity Read ↗

Conformational dynamics of cancer-associated MyD88-TIR domain mutant L252P (L265P) allosterically tilts the landscape toward homo-dimerization.Semantic proximity Read ↗

The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domainSemantic proximity Read ↗

Reconstructing the TIR Side of the Myddosome: a Paradigm for TIR-TIR Interactions.Semantic proximity Read ↗

Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas.Semantic proximity Read ↗

TCR Pathway Mutations in Mature T Cell Lymphomas.Semantic proximity Read ↗

Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphomaSemantic proximity Read ↗

Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.Semantic proximity Read ↗

RHOA controls oncogenic B cell receptor signaling in aggressive lymphoma.Semantic proximity Read ↗

MyD88 adaptor-like D96N is a naturally occurring loss-of-function variant of TIRAP.Semantic proximity Read ↗

MyD88 as a therapeutic target for inflammatory lung diseasesSemantic proximity Read ↗

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.